Cerecor Inc Cmn Stk (CERC) 4.80 $CERC Cerecor A
Post# of 273254
Posted On: 09/22/2016 7:20:06 PM
Cerecor Inc Cmn Stk (CERC) 4.80 $CERC
Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
BusinessWire - Wed Sep 21, 8:10AM CDT
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has completed patient enrollment in its Phase 2 clinical trial for CERC-301, Clin301-203, as an oral, rapidly acting adjunctive treatment of major depressive disorder ("MDD"
. The Company now expects to report top-line data from this trial in November 2016.
CERC: 4.80 (+0.19)
Cerecor Enters Into a $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
BusinessWire - Mon Sep 12, 8:10AM CDT
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has entered into a $15 million common stock purchase agreement (the "Agreement" and a registration rights agreement with Aspire Capital Fund, LLC ("Aspire" , a Chicago-based institutional investor.
CERC: 4.80 (+0.19)
Cerecor Announces Last Patient Enrolled in Phase 2 Clinical Trial with CERC-501 for Smoking Cessation
BusinessWire - Tue Sep 06, 8:10AM CDT
Cerecor Inc. (NASDAQ:CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has completed patient enrollment in its Phase 2 clinical trial for CERC-501, "A Randomized, Double-Blind, Placebo-Controlled, Cross-over Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior." The Company expects to report top-line data from this trial in the beginning of December 2016.
CERC: 4.80 (+0.19)
Cerecor to Present at 23rd Annual NewsMakers in the Biotech Industry Conference in New York City, September 9, 2016
BusinessWire - Thu Sep 01, 8:10AM CDT
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced it will be featured as a presenting company at the 23rd Annual NewsMakers in the Biotech Industry Conference. The conference is being held on September 9, 2016, at the Millennium Broadway Hotel in New York City.
CERC: 4.80 (+0.19)
Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers
BusinessWire - Mon Aug 29, 8:10AM CDT
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company developing innovative drugs that have the potential to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that Dr. Sherry McKee from Yale University has enrolled the first subject in the Phase 2 clinical trial for CERC-501, "Does CERC-501 Attenuate Stress-Related Smoking Lapse?" The study is a collaborative effort between Cerecor and Dr. McKee and is supported by funding from the National Institutes of Health (NIH). "Stress is a primary contributor to the maintenance of, and relapse to, smoking, and targeting stress-related relapse as a medication development strategy is a critical, yet relatively unexplored area of research," says Dr. McKee. "Preclinical findings suggest that the kappa opioid receptor system is involved in stress-induced relapse to tobacco and we anticipate that a receptor antagonist, such as CERC-501, has the potential to be of therapeutic benefit."
CERC: 4.80 (+0.19)
Cerecor Inc. Reports Second Quarter 2016 Financial Results
BusinessWire - Mon Aug 15, 8:10AM CDT
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates to make a difference in the lives of patients with neurological and psychiatric disorders, today announced its financial results for the second quarter ended June 30, 2016.
CERC: 4.80 (+0.19)
Cerecor Inc. Reports First Quarter 2016 Financial Results
BusinessWire - Mon May 16, 8:10AM CDT
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced its financial results for the first quarter ended March 31, 2016.
CERC: 4.80 (+0.19)
Cerecor Announces Initiation of Phase 2 Clinical Trial With CERC-501 for Smoking Cessation
BusinessWire - Tue Feb 02, 8:10AM CST
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that the Company has enrolled its first subject in the Phase 2 clinical trial for CERC-501, "A Randomized, Double-Blind, Placebo-Controlled, Cross-over Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior".
CERC: 4.80 (+0.19)
Cerecor Inc. to Present at the BIO CEO & Investor Conference in New York City
BusinessWire - Mon Feb 01, 8:10AM CST
Cerecor Inc. (NASDAQ:CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it will present at the BIO CEO & Investor Conference taking place February 8-9, 2016, at the Waldorf Astoria in New York City. Dr. Uli Hacksell, CEO, President and Chairman of Cerecor, is scheduled to present at 3 p.m. EST, Monday, February 8, 2016.
CERC: 4.80 (+0.19)
Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model
BusinessWire - Tue Jan 19, 8:10AM CST
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced the publication of preclinical data suggesting antidepressant activity of CERC-301. The paper, titled 'Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist', was published in the December issue of the Journal of Pharmacology Research & Perspectives. This publication reports results of CERC-301 in an acute preclinical depression model known as the forced swim test, a common model of antidepressant efficacy. In test animals, CERC-301 showed antidepressant activity at doses that had minimal side effects.
CERC: 4.80 (+0.19)
Cerecor Inc. Appoints Thomas Aasen to Board of Directors
BusinessWire - Tue Jan 12, 8:10AM CST
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders, today announced Thomas H. Aasen has joined its Board of Directors and will serve on its Audit Committee. Mr. Aasen is a financial executive with over thirty years of professional experience, including financial management positions in four publicly held life science companies.
CERC: 4.80 (+0.19)
Cerecor Inc. to Present at Biotech Showcase 2016 in San Francisco
BusinessWire - Mon Jan 04, 8:10AM CST
Cerecor Inc. (NASDAQ:CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it will present at Biotech Showcase 2016 on Tuesday, January 12, 2016. The presentation is scheduled at 11:30 a.m., PST, in the Parc 55 Hilton Hotel, San Francisco.
CERC: 4.80 (+0.19)
Cerecor Inc. Names Uli Hacksell, Chairman of Cerecor and Former CEO of ACADIA, as President and CEO
BusinessWire - Mon Dec 21, 8:00AM CST
Cerecor Inc. (NASDAQ: CERC) today announced that Uli Hacksell, Chairman of Cerecor and former CEO of ACADIA, has been named to the additional positions of CEO and President of the company as of January 1, 2016. Dr. Blake Paterson will step down as the company's CEO and resign from its board, but will continue to work with the company as a scientific advisor.
CERC: 4.80 (+0.19)
Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501
BusinessWire - Fri Dec 11, 8:15AM CST
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced the publication of data regarding the human brain receptor occupancy of CERC-501, formerly known as LY2456302. In this study of healthy volunteers, CERC-501 demonstrated reproducible penetration of the blood-brain barrier and target engagement, as shown through PET (positron emission tomography) imaging. CERC-501 is a potent and selective oral kappa opioid receptor, or KOR, antagonist being developed to treat depression and substance use disorders, such as alcohol, nicotine and/or illicit drug dependence.
CERC: 4.80 (+0.19), LLY: 81.29 (+0.42)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015 - 30 Companies & 52 Drug Profiles
M2 - Fri Jul 31, 9:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/57stt9/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - Arbor Pharmaceuticals, LLC. - Cerecor Inc. - Collegium Pharmaceutical, Inc. - Curemark, LLC - DURECT Corporation - Eli Lilly and Company - H. Lundbeck A/S - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Merck & Co., Inc. - Mnemosyne Pharmaceuticals, Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Otsuka Holdings Co., Ltd. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/57...on_deficit
KMPH: 4.55 (+0.02), ADHD: 4.70 (-0.02), SUPN: 26.02 (-0.09), COLL: 15.30 (+2.48), LLY: 81.29 (+0.42), DRRX: 1.74 (+0.01), NEOS: 6.89 (+0.13), NDRM: 17.75 (+0.28), CERC: 4.80 (+0.19), SHPG: 204.22 (+0.22), MRK: 63.02 (+0.32), ITCI: 40.87 (-0.02)
Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
BusinessWire - Wed Sep 21, 8:10AM CDT
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has completed patient enrollment in its Phase 2 clinical trial for CERC-301, Clin301-203, as an oral, rapidly acting adjunctive treatment of major depressive disorder ("MDD"
. The Company now expects to report top-line data from this trial in November 2016. CERC: 4.80 (+0.19)
Cerecor Enters Into a $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
BusinessWire - Mon Sep 12, 8:10AM CDT
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has entered into a $15 million common stock purchase agreement (the "Agreement"
and a registration rights agreement with Aspire Capital Fund, LLC ("Aspire" , a Chicago-based institutional investor. CERC: 4.80 (+0.19)
Cerecor Announces Last Patient Enrolled in Phase 2 Clinical Trial with CERC-501 for Smoking Cessation
BusinessWire - Tue Sep 06, 8:10AM CDT
Cerecor Inc. (NASDAQ:CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has completed patient enrollment in its Phase 2 clinical trial for CERC-501, "A Randomized, Double-Blind, Placebo-Controlled, Cross-over Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior." The Company expects to report top-line data from this trial in the beginning of December 2016.
CERC: 4.80 (+0.19)
Cerecor to Present at 23rd Annual NewsMakers in the Biotech Industry Conference in New York City, September 9, 2016
BusinessWire - Thu Sep 01, 8:10AM CDT
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced it will be featured as a presenting company at the 23rd Annual NewsMakers in the Biotech Industry Conference. The conference is being held on September 9, 2016, at the Millennium Broadway Hotel in New York City.
CERC: 4.80 (+0.19)
Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers
BusinessWire - Mon Aug 29, 8:10AM CDT
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company developing innovative drugs that have the potential to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that Dr. Sherry McKee from Yale University has enrolled the first subject in the Phase 2 clinical trial for CERC-501, "Does CERC-501 Attenuate Stress-Related Smoking Lapse?" The study is a collaborative effort between Cerecor and Dr. McKee and is supported by funding from the National Institutes of Health (NIH). "Stress is a primary contributor to the maintenance of, and relapse to, smoking, and targeting stress-related relapse as a medication development strategy is a critical, yet relatively unexplored area of research," says Dr. McKee. "Preclinical findings suggest that the kappa opioid receptor system is involved in stress-induced relapse to tobacco and we anticipate that a receptor antagonist, such as CERC-501, has the potential to be of therapeutic benefit."
CERC: 4.80 (+0.19)
Cerecor Inc. Reports Second Quarter 2016 Financial Results
BusinessWire - Mon Aug 15, 8:10AM CDT
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates to make a difference in the lives of patients with neurological and psychiatric disorders, today announced its financial results for the second quarter ended June 30, 2016.
CERC: 4.80 (+0.19)
Cerecor Inc. Reports First Quarter 2016 Financial Results
BusinessWire - Mon May 16, 8:10AM CDT
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced its financial results for the first quarter ended March 31, 2016.
CERC: 4.80 (+0.19)
Cerecor Announces Initiation of Phase 2 Clinical Trial With CERC-501 for Smoking Cessation
BusinessWire - Tue Feb 02, 8:10AM CST
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that the Company has enrolled its first subject in the Phase 2 clinical trial for CERC-501, "A Randomized, Double-Blind, Placebo-Controlled, Cross-over Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior".
CERC: 4.80 (+0.19)
Cerecor Inc. to Present at the BIO CEO & Investor Conference in New York City
BusinessWire - Mon Feb 01, 8:10AM CST
Cerecor Inc. (NASDAQ:CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it will present at the BIO CEO & Investor Conference taking place February 8-9, 2016, at the Waldorf Astoria in New York City. Dr. Uli Hacksell, CEO, President and Chairman of Cerecor, is scheduled to present at 3 p.m. EST, Monday, February 8, 2016.
CERC: 4.80 (+0.19)
Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model
BusinessWire - Tue Jan 19, 8:10AM CST
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced the publication of preclinical data suggesting antidepressant activity of CERC-301. The paper, titled 'Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist', was published in the December issue of the Journal of Pharmacology Research & Perspectives. This publication reports results of CERC-301 in an acute preclinical depression model known as the forced swim test, a common model of antidepressant efficacy. In test animals, CERC-301 showed antidepressant activity at doses that had minimal side effects.
CERC: 4.80 (+0.19)
Cerecor Inc. Appoints Thomas Aasen to Board of Directors
BusinessWire - Tue Jan 12, 8:10AM CST
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders, today announced Thomas H. Aasen has joined its Board of Directors and will serve on its Audit Committee. Mr. Aasen is a financial executive with over thirty years of professional experience, including financial management positions in four publicly held life science companies.
CERC: 4.80 (+0.19)
Cerecor Inc. to Present at Biotech Showcase 2016 in San Francisco
BusinessWire - Mon Jan 04, 8:10AM CST
Cerecor Inc. (NASDAQ:CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it will present at Biotech Showcase 2016 on Tuesday, January 12, 2016. The presentation is scheduled at 11:30 a.m., PST, in the Parc 55 Hilton Hotel, San Francisco.
CERC: 4.80 (+0.19)
Cerecor Inc. Names Uli Hacksell, Chairman of Cerecor and Former CEO of ACADIA, as President and CEO
BusinessWire - Mon Dec 21, 8:00AM CST
Cerecor Inc. (NASDAQ: CERC) today announced that Uli Hacksell, Chairman of Cerecor and former CEO of ACADIA, has been named to the additional positions of CEO and President of the company as of January 1, 2016. Dr. Blake Paterson will step down as the company's CEO and resign from its board, but will continue to work with the company as a scientific advisor.
CERC: 4.80 (+0.19)
Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501
BusinessWire - Fri Dec 11, 8:15AM CST
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced the publication of data regarding the human brain receptor occupancy of CERC-501, formerly known as LY2456302. In this study of healthy volunteers, CERC-501 demonstrated reproducible penetration of the blood-brain barrier and target engagement, as shown through PET (positron emission tomography) imaging. CERC-501 is a potent and selective oral kappa opioid receptor, or KOR, antagonist being developed to treat depression and substance use disorders, such as alcohol, nicotine and/or illicit drug dependence.
CERC: 4.80 (+0.19), LLY: 81.29 (+0.42)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015 - 30 Companies & 52 Drug Profiles
M2 - Fri Jul 31, 9:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/57stt9/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - Arbor Pharmaceuticals, LLC. - Cerecor Inc. - Collegium Pharmaceutical, Inc. - Curemark, LLC - DURECT Corporation - Eli Lilly and Company - H. Lundbeck A/S - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Merck & Co., Inc. - Mnemosyne Pharmaceuticals, Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Otsuka Holdings Co., Ltd. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/57...on_deficit
KMPH: 4.55 (+0.02), ADHD: 4.70 (-0.02), SUPN: 26.02 (-0.09), COLL: 15.30 (+2.48), LLY: 81.29 (+0.42), DRRX: 1.74 (+0.01), NEOS: 6.89 (+0.13), NDRM: 17.75 (+0.28), CERC: 4.80 (+0.19), SHPG: 204.22 (+0.22), MRK: 63.02 (+0.32), ITCI: 40.87 (-0.02)
(0)
(0)Scroll down for more posts ▼